# A Study of MHB042C in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07192107/  
OnCo record `nct07192107` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MHB042C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.

## Summary

A Study of MHB042C in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07192107 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2025-11-27 and due to reach its primary completion in 2029-10. Interventions recorded: MHB042C for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07192107
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB042C for Injection in Patients With Advanced Solid Tumors
- Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07192107: https://clinicaltrials.gov/study/NCT07192107

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07192107.json